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Variable HR 95% CI P-value
RPA group
G1 (no cytoreduction) 1
G2 (Cytoreduction w/
stable/decreasing blasts)
1.15 0.45-2.98 0.77
G3 (Cytoreduction w/ 3.03 1.11-8.28 0.03
Abstracts / Biol Blood Marrow Transplant 20 (2014) S211eS256 S223patients who had CMV reactivation (58.2  4.9%) compared
to patients without reactivation (68.9  3.7%, p¼0.004).
The incidence of CMV reactivation after SCT is low despite a
high seroprevalence in Indian patients undergoing allogeneic
SCT. CMV reactivation however is associated with a lower
overall survival following allogeneic SCT.increasing blasts)
De novo vs. secondary MDS 3.52 1.07-11.6 0.039
LDH >330 IU/L at HCT 2.69 1.26-5.73 0.01
Blasts at HCT (continuous) 1.05 0.98-1.12 0.16
HCT-CI score
Int vs. Low 1.43 0.62-3.32 0.4
High vs. Low 0.97 0.39-2.45 0.95344
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Background:Many patients with myelodysplastic syndrome
(MDS) undergo cytoreductive chemotherapy to reduce the
marrow blast count prior to allogeneic hematopoietic cell
transplantation (HCT). While pre-HCT disease burden cor-
relates with post-HCT outcome, a dynamic approach of
assessing changes in blast count with therapy has not been
systematically explored.
Methods: Results of 54 consecutive patients transplanted
between 2005-2012 for MDS (43 de novo, 11 secondary) with
full-intensity conditioning regimens (94% with busulfan
/cyclophosphamide) were analyzed. The median age was 50
years (range 20-66). Donors were siblings (33%) or unrelated
(67%); 78% of patients received marrow and 22% peripheral
blood progenitor cells. Recursive partitioning analysis (RPA)
was used to identify groups that are prognostic for overall
survival (OS) based on pre-HCT chemotherapy and change in
blast count. The association of RPA group with outcome was
examined.
Results: RPA identiﬁed three groups: patients who did not
receive pre-HCT cytoreduction (G1), those who did with
subsequent stable/decreased (G2) or increased (G3) blast
count prior to HCT. These groupswere similar with respect to
demographic, disease, and transplant variables, as well as
comorbidity scores (HCT-CI).
Though the grade and incidence of GVHD and relapse
were similar, OS (Figure, P ¼ 0.02, log-rank) and NRM (P ¼
0.08, Gray test) were inferior for patients who had an in-
crease in blast count after pre-HCT cytoreduction. Three-year
OS was 54%, 43%, and 12%, respectively, for G1, G2, and G3;
3-year NRM was 31%, 34%, and 81%. Mortality at 100 days
was 23%, 7%, and 46% for G1, G2, and G3, respectively (P ¼
0.16). A clear pattern for cause of NRM in G3 versus G1/G2
could not be discerned.
Pre-HCT blast count and comorbidities were not associ-
ated with OS in univariate analysis (Table). In multivariate
analysis, pre-HCT chemotherapy with an increase in blast
count remained associated with a worse survival relative to
no prior chemotherapy (HR 3.08, 95% CI 1.13-8.43, P ¼ 0.028.
Conclusions: Counterintuitively, the inferior survival of G3
was not due to relapse, but mainly NRM, particularly early
mortality, despite similar HCT-CI scores. This result suggests
that thosewho progress despite pre-HCTchemotherapy with
an unacceptably high risk of NRM, may not beneﬁt from HCT.This analysis cannot determine if pre-HCT cytoreduction is
beneﬁcial or detrimental, and should be carefully assessed in
prospective studies.
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Background: CMV infection remains an important cause of
morbidity & mortality in CBT recipients. The objective of this
study was to determine the incidence and to examine the
characteristics & outcome of CMV infections in 95 CBT
recipients.
Methods:We identiﬁed CBT recipients whowere cared for at
our institution between 2000 & 2007 from the Stem Cell
Transplant databases. Data on demographics, underlying
cancer, risk factors for CMV reactivation, CMV prophylaxis,
CMV serostatus & outcomes were collected. Multivariate lo-
gistic regression analyses (MVA) were applied to identify
Abstracts / Biol Blood Marrow Transplant 20 (2014) S211eS256S224predictors of CMV infection, CMV end organ disease and all-
cause mortality.
Results: Median age was 27y (range: 0.8-66y) and the ma-
jority were men (58%). A total of 36 (49%) patients had CMV
infection out of 74 (78%) CMV seropositive recipients. CMV
infection occurred at a median of 38 days after CBT (range: -1
- +927d). Most patients had GvHD (56%), received steroids
(34%), and immunosuppressive therapy (87%), mainly
tacrolimus prior to CMV infection. Whether CBT recipients
received CMV prophylaxis (between day -10 to -3) or not, the
incidence of CMV reactivationwas not statistically signiﬁcant
(37% vs. 43%, respectively). Progression to CMV end organ
disease occurred in 6 patients at an incidence of 6% and
mainly affected the gastrointestinal (GI) tract. CMV-associ-
ated mortality occurred in only 1 patient with CMV pneu-
monia. Non relapse related mortality occurred in 25 (26%) of
CBT recipients and was not different when stratiﬁed by CMV
serostatus and CMV reactivation. Univariate analysis
revealed that CMV-seropositive recipients with leukemia
had higher risk of developing CMV infection compared to
seropositive patients with lymphoma (83% vs.17%; p¼0.039).Figure 1. No signiﬁcant difference in day 0 F-ara-A levels between patients with vs w
therapy (25,000 IU/mL plasma), post-transplant lymphoproliferative disorder (PTLD), r
p was >0.05 (range,0.22-0.78). Mann-Whitney-Wilcoxon test was used. “cGVHD NSTAmong CMV-seropositive recipients, more pts with CMV
infection were transferred to ICU (56% vs. 34%; p¼0.046) and
needed mechanical ventilation (36% vs. 21%; p¼0.121). MVA
did not yield any signiﬁcant predictors of CMV infection.
Conclusion: CMV infection after CBT is common and occurs
early on after transplant. Patients with leukemia are at
higher risk of this complication after CBT. Interestingly, CMV
end-organ disease was not common and mainly affected the
GI tract in this patient population.346
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